Dual Antiplatelet and Oral Anticoagulant Therapy. Increasing Use and Precautions for a Hazardous Combination**Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.

JACC: Cardiovascular Interventions

Volumn 1, Issue 1, 2008, Pages 62-64

  Hylek, Elaine M ^a   Solarz, David E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; TICLOPIDINE; WARFARIN;

AGE DISTRIBUTION; ANAMNESIS; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY STENT; EDITORIAL; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HELICOBACTER INFECTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; PEPTIC ULCER; PEPTIC ULCER BLEEDING; POLYPHARMACY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STROKE; THROMBOSIS; TREATMENT INDICATION; ULCER PERFORATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CORONARY RESTENOSIS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; INCIDENCE; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; TREATMENT OUTCOME;

EID: 41249102714     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2007.11.005     Document Type: Editorial

References (20)

1. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmstead County, Minnesota, 1980-2000, and implications on the projections for future prevalence. Circulation 114 (2006) 119-125
2. Wysowski D.K., Nourjah P., and Swartz L. Bleeding complications with warfarin use. Arch Intern Med 167 (2007) 1414-1419
3. Hylek E.M., Evans-Molina C., Shea C., Henault L.E., and Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115 (2007) 2689-2696
4. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357 (2007) 217-227
5. Rogacka R., Chieffo A., Michev I., et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. J Am Coll Cardiol Intv 1 (2008) 56-61
6. Orford J.L., Fasseas P., Melby S., et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 147 (2004) 463-467
7. Khurram Z., Chou E., Minutello R., et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 18 (2006) 162-164
8. Karjalainen P.P., Porela P., Ylitalo A., et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 28 (2007) 726-732
9. Hernández-Díaz S., and García Rodríguez L.A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 4 (2006) 22
10. Delaney J.A., Opatrny L., Brophy J.M., and Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 177 (2007) 347-351
11. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E.M. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 204S-233S
12. Levine M.N., Raskob G., Beyth R.J., Kearon C., and Schulman S. Hemorrhagic complications of anticoagulant treatment. Chest 126 (2004) 287S-310S
13. The ACTIVE Writing Group on Behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of Vascular Events (ACTIVE W). Lancet 367 (2006) 1903-1912
14. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee on Practice Guidelines. J Am Coll Cardiol 48 (2006) 854-906
15. Hart R.G., Tonarelli S.B., and Pearce L.A. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 36 (2005) 1588-1593
16. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
17. Chey W.D., Wong B.C., and Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102 (2007) 1808-1825
18. Wiviott S.D., Braunwald E., McCabe C.H., et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
19. Lanas A., Garcia-Rodriquez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515
20. Nguyen M.C., Lim Y.L., Walton A., et al., GRACE Investigators. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. Eur Heart J 28 (2007) 1717-1722